Studies show that in early AD pathology, TREM2 is needed for clearance of early Aβ plaques and slowing of cognitive decline, while expression of TREM2 later in disease progression could lead to detrimental long-term consequences (88–92). The gene discussed is TREM2; the disease is Alzheimer disease.